Literature DB >> 2537428

Modification of the hydroxy lactone ring of camptothecin: inhibition of mammalian topoisomerase I and biological activity.

R P Hertzberg1, M J Caranfa, K G Holden, D R Jakas, G Gallagher, M R Mattern, S M Mong, J O Bartus, R K Johnson, W D Kingsbury.   

Abstract

Several camptothecin derivatives containing a modified hydroxy lactone ring have been synthesized and evaluated for inhibition of topoisomerase I and cytotoxicity to mammalian cells. Each of the groups of the hydroxy lactone moiety, the carbonyl oxygen, the ring lactone oxygen, and the 20-hydroxy group, were shown to be critical for enzyme inhibition. For example the lactol, lactam, thiolactone, and 20-deoxy derivatives did not stabilize the covalent DNA-topoisomerase I complex. With a few exceptions, those compounds that did not inhibit topoisomerase I were not cytotoxic to mammalian cells. Two cytotoxic derivatives that did not inhibit topoisomerase I were shown to produce non-protein-associated DNA single-strand breaks and are likely to have a different mechanism of action. One of these compounds was tested for antitumor activity and was found to be inactive. The present findings, as well as other reports that the hydroxy lactone ring of camptothecin is critical for antitumor activity in vivo, correlate with the structure-activity relationships at the level of topoisomerase I and support the hypothesis that antitumor activity is related to inhibition of this target enzyme.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2537428     DOI: 10.1021/jm00123a038

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  51 in total

1.  The mechanism of topoisomerase I poisoning by a camptothecin analog.

Authors:  Bart L Staker; Kathryn Hjerrild; Michael D Feese; Craig A Behnke; Alex B Burgin; Lance Stewart
Journal:  Proc Natl Acad Sci U S A       Date:  2002-11-08       Impact factor: 11.205

Review 2.  New cytotoxic drugs for intrathecal administration.

Authors:  S M Blaney; D G Poplack
Journal:  J Neurooncol       Date:  1998 Jun-Jul       Impact factor: 4.130

Review 3.  Mechanized silica nanoparticles: a new frontier in theranostic nanomedicine.

Authors:  Michael W Ambrogio; Courtney R Thomas; Yan-Li Zhao; Jeffrey I Zink; J Fraser Stoddart
Journal:  Acc Chem Res       Date:  2011-06-15       Impact factor: 22.384

4.  Molecular docking approach on the Topoisomerase I inhibitors series included in the NCI anti-cancer agents mechanism database.

Authors:  Antonino Lauria; Mario Ippolito; Anna Maria Almerico
Journal:  J Mol Model       Date:  2006-10-28       Impact factor: 1.810

5.  Pharmacokinetics and pharmacodynamics of topotecan administered daily for 5 days every 3 weeks.

Authors:  L J van Warmerdam; J Verweij; J H Schellens; H Rosing; B E Davies; M de Boer-Dennert; R A Maes; J H Beijnen
Journal:  Cancer Chemother Pharmacol       Date:  1995       Impact factor: 3.333

6.  Stable supersaturated aqueous solutions of silatecan 7-t-butyldimethylsilyl-10-hydroxycamptothecin via chemical conversion in the presence of a chemically modified beta-cyclodextrin.

Authors:  Tian-Xiang Xiang; Bradley D Anderson
Journal:  Pharm Res       Date:  2002-08       Impact factor: 4.200

7.  Plasma pharmacokinetics of lactone and carboxylate forms of 20(S)-camptothecin in anesthetized rats.

Authors:  D O Scott; D S Bindra; V J Stella
Journal:  Pharm Res       Date:  1993-10       Impact factor: 4.200

8.  DNA topoisomerases from pathogenic fungi: targets for the discovery of antifungal drugs.

Authors:  L L Shen; J Baranowski; J Fostel; D A Montgomery; P A Lartey
Journal:  Antimicrob Agents Chemother       Date:  1992-12       Impact factor: 5.191

9.  Characterization of DNA topoisomerase I from Candida albicans as a target for drug discovery.

Authors:  J M Fostel; D A Montgomery; L L Shen
Journal:  Antimicrob Agents Chemother       Date:  1992-10       Impact factor: 5.191

10.  A novel camptothecin derivative incorporated in nano-carrier induced distinguished improvement in solubility, stability and anti-tumor activity both in vitro and in vivo.

Authors:  Min Han; Cai-Xia He; Qiu-Li Fang; Xiao-Chun Yang; Yuan-Yuan Diao; Dong-Hang Xu; Qiao-Jun He; Yong-Zhou Hu; Wen-Quan Liang; Bo Yang; Jian-Qing Gao
Journal:  Pharm Res       Date:  2008-12-02       Impact factor: 4.200

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.